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High dose chemotherapy with autologous stem cell
transplantation in diffuse large B-cell lymphoma
HochdosistherapiemitautologerStammzelltransplantationbeiPatienten
mit diffus großzelligem Non-Hodgkin-Lymphom
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Medicine I, University of
Bonn, Bonn, Germany
chemosensitive patients with incomplete response to first line therapy,
and patients with chemosensitive relapsed disease was 87.5%, 50.0%
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Hematology and Transfusion disease or relapsed disease lacking chemosensitivity lived longer than
8 months. Chemosensitivity was the only significant prognostic factor
for overall survival (OS) in multivariate analysis.
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Conclusions:OurresultsconfirmthatHDTandASCTisahighlyeffective
therapy in patients with DLBCL leading to long-term survival in a sub-
stantial proportion of patients. Patients treated upfront for high-risk
disease, incomplete response to conventional first-line therapy, or for
chemosensitive relapse have a good prognosis. In contrast, patients
withprimarychemorefractorydiseaseandpatientswithrelapseddisease
lacking chemosensitivity do not benefit from HDT with ASCT.
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Zusammenfassung
Hintergrund:DieHochdosistherapie(HDT)mitautologerStammzelltrans-
plantation (SZT) spielt in der Behandlung aggressiver Non-Hodgkin-
Lymphome(NHL)einegroßeRolle.WirpräsentierendieErgebnisseeiner
retrospektiven Analyse sämtlicher Patienten mit diffus großzelligem
Non-Hodgkin-Lymphom (DLBCL), die im Zeitraum zwischen 1996 und
2004 an der Universitätsklinik Bonn mittels HDT und nachfolgender
autologer SZT behandelt worden sind.
Methoden: Insgesamt wurden 25 Patienten mit bioptisch gesichertem
DLBCL transplantiert. Bei acht Patienten erfolgte die HDT als geplanter
Bestandteil der Erstlinientherapie („up-front“), vier Patienten wurden
wegen inkompletten Ansprechens und sechs wegen primärer Refraktä-
rität auf die konventionelle Chemotherapie transplantiert. Sieben Pati-
enten erhielten die HDT wegen eines Rezidivs des DLBCL.
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Research Article OPEN ACCESSErgebnisse: Eine komplette Remission wurde bei 14 der 25 Patienten
(56%)erreicht.Diegeschätzten3-Jahres-ÜberlebensratenvonPatienten,
die die HDT als Teil der Erstlinientherapie erhielten, lag bei 87,5%; für
chemosensitive Patienten mit inkomplettem Ansprechen auf die Erstli-
nientherapieundPatientenmitchemosensitiverrezidivierterErkrankung
lagen die entsprechenden Werte bei 50% bzw. 60%. Demgegenüber
lebte in der Gruppe der primär refraktären bzw. rezidivierten Patienten
ohne erhaltene Chemosensitivität kein Patient länger als 8 Monate. In
der multivariaten Analyse prognostisch relevanter Faktoren für das
GesamtüberlebenerwiessichChemosensitivitätalseinzigsignifikanter
Parameter.
Schlussfolgerung:UnsereErgebnissezeigen,dassdieHDTmitnachfol-
genderSZTinderBehandlungvonPatientenmitDLBCLeinehocheffek-
tive Therapie darstellt, die bei einem Großteil der Patienten ein Lang-
zeitüberlebenermöglicht.Patienten,diedieHDTinHochrisikosituationen
alsTeilderErstlinientherapieerhaltenoderwegeninkomplettenAnspre-
chens auf konventionelle Chemotherapie bzw. im chemosensiblen Re-
zidiv transplantiert werden, haben eine gute Prognose. Im Gegensatz
dazu profitieren Patienten mit primär refraktärer Erkrankung und Pati-
enten mit chemoresistentem Rezidiv nicht von einer HDT.
Schlüsselwörter: diffus großzelliges Non-Hodgkin-Lymphom,
Hochdosistherapie, autologe Stammzelltransplantation
Introduction
High-dose chemotherapy (HDT) followed by autologous
stem cell transplantation (ASCT) is an established treat-
ment approach for certain subgroups of patients with
aggressive non-Hodgkin’s lymphoma (NHL). For patients
with relapsed aggressive NHL sensitive to second-line
salvagechemotherapy,prolongedevent-freesurvivalhas
been demonstrated in the well-known Parma trial [1]. As
a result of this single randomised trial, HDT with ASCT is
widely accepted as standard treatment in this patient
population.
Although some phase I/II trials have reported favourable
resultsforHDTwithASCTasfirst-linetherapyforpatients
consideredtobeathighriskforrelapse,resultsoflarger,
prospective randomised trials have been contradictory
[2],[3],[4],[5],[6],[7],[8],[9],[10].Insometrialsapply-
ingtheinternationalprognosticindex(IPI)retrospectively,
patientswithhigh-intermediateandhigh-riskprofileshad
significantly better results with HDT followed by ASCT
thanthosetreatedwithconventionalchemotherapy[11],
[12], [13], [14], [15]. As a consequence, more recently
designed trials prospectively evaluated the effect of HDT
with ASCT in consideration of the IPI. In a meta-analysis
of eleven randomised trials comparing HDT with ASCT to
conventional chemotherapy, HDT/ASCT was superior in
terms of OS in high and high-intermediate risk patients
when this strategy is used after maximum tumour reduc-
tionhasbeenachieved[16].However,combinedanalysis
of the different available trials is hampered - if not im-
possible-duetoconsiderableheterogeneitybetweenthe
trialsintermsofpatientselectionaswellasstudydesign.
AssuperiorityofHDTfollowedbyASCTinfirstlinetherapy
of aggressive NHL has still not been conclusively
demonstrated, this treatment approach has still to be
considered experimental and is a source of ongoing
controversial discussions.
The answer to the question whether HDT is appropriate
in patients with chemorefractory first or subsequent re-
lapse or primary refractory disease is controversial and
madedifficultduetothelackofuniformcriteriatodefine
chemorefractoriness disease in different clinical trials.
Jurymembersofan“InternationalConsensusConference
on High-Dose Therapy with Haematopoietic Stem Cell
Transplantation in Aggressive NHL” held in April 1998
agreed that HDT was not indicated for chemorefractory
first or subsequent relapse [17]. On the other hand, a
small subset of patients with primary refractory disease
might benefit from HDT [18], [19], [20], [21]. Therefore,
some patients with induction failure can have long-term
disease-free survival with HDT and ASCT.
In an attempt to contribute to the available information
regarding the role of HDT with ASCT in NHL treatment,
we here report on a detailed retrospective analysis of all
consecutively treated patients with diffuse large B-cell
lymphoma who were treated with HDT and ASCT at the
UniversityHospitalofBonn,Germany,between1996and
2004. Subgroup analysis and univariate as well as
multivariate analysis with regard to factors predicting
outcome are presented. Results are discussed against
the background of the existing body of evidence.
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Patients
Between 1996 and 2004, a total of 52 patients under-
went high-dose chemotherapy (HDT) with autologous
stemcelltransplantation(ASCT)formalignantlymphoma
at the University hospital of Bonn, Germany. To ensure
homogeneity of the analysed population and to exclude
selectionbiasduetodifferenthistologies,thisretrospect-
ive analysis includes 25 patients with biopsy-proven dif-
fuselargeB-celllymphoma(DLBCL)only.Allpatientshad
adequate organ function as defined by a creatinine
clearance more than 60 ml/min; adequate cardiac func-
tion (ejection fraction ≥50%), serum transaminases less
than three times the normal value; bilirubin less than 3
mg/dl; adequate haematopoietic sufficiency (leukocyte
count ≥3.0 G/l and platelet count ≥80 G/l), no active
uncontrolled infection or human immunodeficiency virus
(HIV)-positive serology, and an performance status of ≥2
according to the Eastern Cooperative Oncology Group
classification scale.
Determination of disease status pre-
transplant
For operative purposes, pre-transplant disease status as
well as indication for HDT followed by ASCT was categor-
ised as follows: All patients who received HDT with ASCT
as upfront induction therapy in form of a “high-dose se-
quential therapy” and patients undergoing consolidative
HDTwithASCTafterachievingacompleteremission(CR)
with conventional induction therapy were grouped
together.PatientsfailingtoachieveaCRtoanthracycline-
based 1
st-line chemotherapy were separated in two
groups: Patients with only incomplete response to con-
ventional induction chemotherapy achieving at least a
partial remission (PR) after subsequent pre-transplant
salvage chemotherapy were considered to have primary
refractory, chemosensitive disease. In contrast, patients
with either progressive disease (PD) during first-line
chemotherapy or only stable disease (SD) or PD after
completion of induction therapy or failing to respond to
subsequent pre-transplant salvage chemotherapy were
defined to have primary refractory, chemoresistant dis-
ease. Similarly, patients with relapsed disease were
separated according to their response to salvage
chemotherapy: Chemorefractory relapse was defined as
SD or PD after two courses of an aggressive salvage regi-
men, whereas achievement of at least a PR after two
cycles of aggressive salvage therapy was regarded as
chemosensitive relapsed disease.
Staging, follow-up and response criteria
Initial staging procedures at first diagnosis or time of re-
lapsefollowedstandardguidelines.Physicalexamination,
complete blood counts, serum chemistry, bone marrow
aspiration and biopsy, and radiological studies were per-
formed in all cases. Restaging examinations were per-
formed after every two courses of conventional therapy,
immediately pre-transplant and four weeks after
HDT/ASCT.Duringthefirsttwoyearsoffollow-up,physical
examination, laboratory examinations and CT scans or
ultrasonography of involved regions were repeated every
three months. During the third and fourth year post-
transplant, follow-up visits were scheduled every six
months and annually thereafter.
Response was assessed according to standardised
criteria following the recommendations of a National
Cancer Institute (NCI)-sponsored international working
group [22]. Patients were classified according to the in-
ternational prognostic index (IPI) at diagnosis or at time
of relapse according to the original publication [23].
Stem cell harvest and cryopreservation
Thesourceofhaematopoieticprogenitorswasperipheral
bloodinallpatients.Harvestedperipheralstemcellswere
processed on a COBE
®SpectraTM separator and the
mononuclear cells were cryopreserved in 10% dimethyl-
sulfoxide (DMSO) with 20% autologous plasma and kept
inliquidnitrogen.Qualitytestingincludedviabilitytesting
andassessmentofthecolonyformingunit(CFU)capacity.
Maximum period of stem cell storage has been limited
by internal standards to 5 years.
Transplantation procedure
Patients received one of the following conditioning regi-
mens: Mega-CHOEP (cyclophosphamide 1500 mg/m
2,
adriamycin 70 mg/m
2, vincristine 2 mg, etoposide 800
mg/m
2, and prednisone 500 mg (1
st course), cyclophos-
phamide2250mg/m
2,adriamycin70mg/m
2,vincristine
2 mg, etoposide 960 mg/m
2, and prednisone 500 mg
(2
ndand3
rdcourse),andcyclophosphamide6000mg/m
2,
adriamycin 70 mg/m
2, vincristine 2 mg, etoposide 1480
mg/m
2,andprednisone500mg(4
thcourse):11patients;
BEAM (BCNU 300 mg/m², etoposide 1200 mg/m²,
cytosine arabinoside 1600 mg/m², and melphalan 140
mg/m²): 6 patients; CEI (carboplatin 1500 mg/m²,
etoposide 2400 mg/m² and ifosfamide 10 g/m²): 5 pa-
tients; CEIAP (carboplatin 1000 mg/m², etoposide 1200
mg/m², ifosfamide 7500 mg/m², adriamycin 50 mg/m²,
dexamethasone 60 mg): 2 patients; and the IC regimen
(thiotepa750mg/m
2,busulfan10mg/kg,andcyclophos-
phamide 120 mg/kg) in one patient. Stem cells were in-
fused on day 0.
Supportive care during neutropenic
phase
All patients were treated in single- or two-bed rooms. Pa-
tients received a diet low in bacterial and fungal content.
Antimicrobical, antifungal, and antiviral prophylaxis con-
sisted of oral co-trimoxazole, itraconazole, amphotericin
suspension,andacyclovir,respectively.Parenteralantibi-
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ropenia and maintained until defervescence for at least
three consecutive days. In the absence of significant
bleeding, platelet transfusions were administered as re-
quired to maintain a platelet count of greater than 10 x
10
9/L. Transfusions of packed red blood cells were given
on an individual basis. In most patients, a target haemo-
globin concentration of >8 g/dl was aimed at. A decision
on the administration of granulocyte colony-stimulating
factor(G-CSF;filgrastim)wasmadeonanindividualbasis.
Parenteralnutritionandanalgetictreatmentformucositis
was used as clinically indicated.
Toxicity
Toxicity was assessed according to the common toxicity
criteria of the National Cancer Institute.
Statistical analysis
Demographicsanddiseasecharacteristicsweresummar-
ised using descriptive statistics. Survival analysis was
performed using the Kaplan-Meier method and by apply-
ing the log rank test. Overall survival was measured from
entry onto trial until death from any cause. Progression-
free survival was measured from the time of entry onto
study until disease progression or death from NHL. Sur-
vivalwasanalysedusingthemethodofKaplanandMeier
and was compared between groups using the log-rank
test.
To determine prognostic factors for overall survival, pa-
tientcharacteristicsweresubjectedtounivariateanalysis
for each of the following variables: age (≤50 vs. >50
years), sex, disease stage (I or II versus III or IV according
to Ann Arbor), performance status (ECOG 0 vs. ECOG 1
or 2), baseline lactate dehydrogenase (LDH) levels,
number of involved extranodal sites (≤1 vs. >1), number
of prior chemotherapy regimens (≤1 vs. >1), IPI (low or
low-intermediatevs.high-intermediateorhigh),presence
of bulky disease, presence of bone marrow involvement,
numberofHDTcoursesapplicated,chemosensitivityprior
totransplantation,andpre-transplantationdiseasestatus
(CR vs. not in CR).
All tests were two-sided and the level of significance was
set to 0.05. Multivariate analysis with those variables of
at least borderline significance in univariate analysis (p-
value<0.08)wasperformedaccordingtotheCoxpropor-
tional hazard regression model. Statistical calculations
were performed using SPSS software (version 11.0.1).
Results
Efficacy and toxicity as well as long-term follow-up data
were available for all but one patient, who was lost to
follow-up due to non-European residency.
Patient characteristics
Baseline clinical features of all patients are shown in
Table 1. Eight patients received up-front HDT/ASCT or
consolidative HDT followed by ASCT after achievement
of a CR to conventional first-line therapy, ten patients
received HDT/ASCT for induction failure. Four of these
patients had an incomplete response to conventional in-
duction chemotherapy still responsive to salvage
chemotherapywhilesixpatientswerecategorisedtohave
primary refractory, chemoresistant disease. Seven pa-
tients had recurrent lymphoma. Chemosensitive relapse
was present in five patients whereas two patients were
treated for chemoresistant disease.
Thirteen of 25 (52%) patients had high-intermediate or
high risk disease according to the IPI. Bulky disease was
present in 40% of patients and 3 of 25 (12%) had bone
marrow involvement. The baseline LDH level at time of
diagnosis or time of relapse was elevated in 23 of 25
(92%) patients. Two patients were in CR prior to trans-
plantation.
Efficacy
Response rates and survival data are summarised in
Table 2. After HDT followed by ASCT, a CR rate of 56%
was achieved. Patients treated with up-front HDT/ASCT
had the best outcome with 87.5% patients achieving a
CR or CRu. Six of eight patients in this group had at least
anIPIscore≥3andallhadelevatedLDHlevelsatdiagno-
sis. CR and overall remission rates (ORR) did not differ
significantly between patients with chemosensitive re-
lapseorpatientswithonlyincompleteresponseto1
st-line
therapybutchemosensitivedisease.Incontrast,noneof
theprimaryrefractory,chemoresistantpatients,andonly
one patient in the relapsed chemorefractory patient
group, achieved a CR.
Survival curves for patients with different pre-transplant-
ation disease status are shown in Figure 1. According to
the log-rank test, a highly significant difference with re-
gard to overall survival was observed. Whereas median
survival in patients treated with upfront HDT/ASCT or
patients with chemosensitive disease has not been
reached, none of the ten patients with chemorefractory
disease pre-transplant achieved long-term disease free
survivalaftertransplantation.Incontrast,neitherdisease
stage (Ann Arbor stage I or II versus III or IV) nor IPI score
(loworlow-intermediateversushigh-intermediateorhigh)
had a significant impact on overall survival.
Atamedianfollow-upof42months(10-110),12patients
(48%) are alive. Causes of death were PD in ten patients
(40%) and three patients 12% died of infectious compli-
cations, all of whom were directly related to the immun-
osuppression during the transplantation-procedure. No
secondary malignancies or myelodysplastic syndrome
(MDS) have been recorded to date.
4/11 GMS German Medical Science 2007, Vol. 5, ISSN 1612-3174
Mey et al.: High dose chemotherapy with autologous stem cell transplantation ...Table 1: Patient characteristics
5/11 GMS German Medical Science 2007, Vol. 5, ISSN 1612-3174
Mey et al.: High dose chemotherapy with autologous stem cell transplantation ...Table 2: Efficacy: Remission rates after HDT followed by ASCT and 3-year OS
Figure 1: Kaplan-Meier curve of overall survival according to disease status pre-transplant
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Analysis of pre-transplant prognostic
factors for OS
Performance status, presence of chemosensitivity and
LDH baseline levels were of prognostic importance with
regard to OS in univariate analysis and were entered into
multivariateCoxregressionanalysis.Onlychemosensitiv-
ity to salvage chemotherapy pre-transplant remained
predictive of OS (p=0.001). Table 3 lists the p-values for
OS.
Toxicity
HDT with ASCT was associated with substantial
haematologic as well as non-haematologic toxicities. All
25patientsachievedcompletehaematologicengraftment
withabsoluteneutrophilcounts>0.5×G/lafteramedian
of 10 days (range, 4 to 30 days) and a self-sustaining
platelet count >50 × G/l after a median of 9 days (range,
3 to 25 days). 19 patients (76%) received G-CSF for a
median of 10 (2–15) days. Twenty patients (80%) re-
quired packed red cell transfusions (median 4 units).
Platelet transfusions were given to 23 (92%) of patients
(median 2 units). There were three deaths, all of whom
were infection-related. Detailed information on severe
non-haematologic toxicities is provided in Table 4. No
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chemotherapy followed by autologous transplantation for diffuse large B-cell lymphoma
casesofsecondaryacutemyeloidleukemia(AML)orMDS
were documented.
Discussion
In this paper, we present outcome data of all patients
with diffuse large B-cell lymphoma (DLBCL) who have
been treated with high-dose chemotherapy (HDT) and
autologous stem cell transplantation (ASCT) between
1995 and 2004 at the University Hospital of Bonn, Ger-
many.Themainpurposewastodescribelong-termresults
and to provide prognostic factors for outcome with long-
term overall survival as the primary endpoint.
In our analysis, median survival for the whole patient
group was 17.1 months. However, large differences were
seen between subgroups: For patients treated with up-
frontorconsolidativeHDTafterachievementofaCRwith
conventional induction therapy as well as for patients
with chemosensitive relapse, median OS has not been
reachedyet.OSforpatientswithanincompleteresponse
tofirst-linechemotherapystillchemosensitivetosalvage
chemotherapy was 13.4 months. In contrast, patients
with either chemoresistant relapse or primary refractory
chemoresistant disease had no benefit from treatment
with HDT followed by ASCT, achieving a median OS of
less than 5 months.
Several groups have focused on the development of
prognostic models capable of predicting outcome in pa-
tients with recurrent or refractory aggressive lymphoma.
The most widely accepted prognostic factor is chemo-
sensitivitytoconventionaldosesecond-linechemotherapy
[24], [25]. Several additional factors like presence of
bulky disease, three or more chemotherapy regimens
prior to HDT, elevated LDH levels, short time to relapse,
and high disease burden may also have some prognostic
value [26], [27], [28], [29]. However, as a result of the
inhomogeneous patient populations used to generate
these models, no single prognostic model has achieved
widespread acceptance in the setting of relapsed or re-
fractory disease.
In our evaluation, only performance status and chemo-
sensitivity were correlated with OS in univariate analysis
with LDH baseline level reaching merely borderline
significance.Inmultivariateanalysis,onlychemosensitiv-
ity remained to be of prognostic value. The small sample
sizeofourtriallimitsthepowerofthestatisticalanalysis.
Prince et al. tested the hypothesis that the amount of
tumour burden - reflected by the remission status imme-
diately prior to transplant - is an important prognostic in-
dicatorofsurvivalforpatientswithaggressivelymphoma
undergoing autologous transplantation for relapsed or
refractorydisease[28].Patientswithincompleteresponse
to induction therapy or relapsed disease who achieved
only a partial remission (PR) with conventional dose sal-
vage chemotherapy had a markedly inferior outcome
after subsequent HDT with ASCT than patients who were
transplanted in complete remission (CR) state. In fact,
remissionstatusattransplantwastheonlyfactorpredict-
iveofoutcomeinthisanalysis.Thisfindingisofparticular
importance,sinceitsuggeststhehypothesisthatincreas-
ing the CR rate prior to transplant with improved conven-
tional salvage therapies might translate into superior
outcomes after HDT with ASCT for relapsed or refractory
patients with aggressive NHL.
In this regard, we and others have recently reported on
improved CR rates with the addition of the monoclonal
antibody rituximab to conventional salvage regimens for
relapsed or refractory NHL patients [30], [31], [32].
However, whether increasing the CR rate pre-transplant
will finally translate into a significant survival advantage
remains a critical question to be resolved in larger pro-
spective trials with longer follow-up [33].
Special attention should be given to those patients with
primary refractory disease or chemorefractory relapse.
The role of HDT followed by ASCT for these patients has
not been defined because there have been no random-
ised trials in this group of patients to date. Furthermore,
the prognostic importance of chemosensitivity in the ex-
isting studies is biased by the inclusion of patients with
varioushistologicdiagnoses,thelackofchemosensitivity
determination and - in particular - the different applied
definitionsfor“refractorydisease”.Thus,notwithstanding
the limitations of our evaluation due to its small number
ofpatients,astrengthofthisanalysismightbethediffer-
entiated categorization of patients in terms of their dis-
ease status and grade of chemosensitivity.
Studies on HDT with ASCT for patients with induction
failure – i.e. non-achievement of a CR to conventional
induction chemotherapy – have reported progression-
free-survival rates of 27%-69% [4], [34], [35], [36], [37].
The largest available data set of patients with diffuse
aggressive NHL undergoing autologous transplantation
after not achieving CR with induction chemotherapy was
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evaluation of the 184 records from the Autologous Blood
and Marrow Transplant Registry demonstrated 5-year
probabilitiesofPFSandOSof31%and37%,respectively.
Patients who remained chemotherapy-sensitive, had a
good performance status, were younger than 55 years
of age, had received only one or two prior chemotherapy
regimens,andhadreceivedeitherpre-orpost-transplant
involved-field irradiation, did benefit most from this ap-
proach. Consequently, HDT has been accepted by many
physicians for the treatment of patients with primary re-
fractory disease provided that chemotherapy sensitivity
isdocumentedaftersalvagechemotherapy.Theseresults
have been confirmed in a Spanish retrospective analysis
of 114 patients who failed to achieve a CR with 1st-line
induction chemotherapy and received HDT/ASCT as part
of their salvage treatment [37]. The 60% 3 year OS rate
in patients with chemosensitive relapsed disease in our
seriesiswellinlinewiththeresultsreportedbytheabove
mentionedtrialswith45%-60%ofpatientsachievinglong-
term survival.
In contrast, the outcome of patients with “truly”
chemorefractory disease is very poor. Five-year survival
rates are only about 10% in almost all published reports
[19],[29],[38],[39],[40].InthePARMAtrial,18patients
not responding to two courses of dexamethasone/high-
dose ara-C/cisplatin (DHAP) received HDT followed by
autologousbonemarrowtransplantation(ABMT).Ofnote,
at least for patients with a low risk IPI score, a significant
survival benefit was found in transplanted patients com-
pared to the 70 remaining patients not undergoing
HDT/ASCT [41]. Very recently, Glossmann et al. reported
on their experiences with tandem transplantation in pa-
tients with primary progressive or relapsed lymphoma
refractory to salvage treatment [42]. Tandem HDT fol-
lowed by ASCT offered a small chance for cure at least
for some patients in their series, leading the authors to
conclude that patients lacking chemosensitivity should
not a priori be excluded from transplant procedures. This
is in particular true for younger patients, who are often
willing to take the high risk of treatment failure as there
might be a small chance for long-term survival.
The results of a very recently published retrospective
analysisof57outof425relapsedorrefractorylymphoma
patients (17 Hodgkin’s disease, 26 aggressive NHL, 14
indolent NHL) who received a second salvage regimen
after failure of the first salvage regimen are helpful to
more precisely assess the relevance of chemosensitivity
in the treatment of aggressive NHL: From 15 patients
withSDfollowingfirstsalvagetherapy,fivepatients(33%)
achieved a response to second salvage chemotherapy
as opposed to only one of 24 (4%) patients with PD after
firstsalvagetreatment[21].The3-yearestimatedsurvival
was 25% in the former group as opposed to only 4% in
thelattergroup(theonlypatientwhosurvivedlongerthan
3 years in this group had indolent lymphoma). These ob-
servations are well in line with our experiences: All pa-
tients with PD to salvage chemotherapy died in less than
eight months after HDT/ASCT. Thus, our results support
the view that patients who undoubtedly show PD after
conventional salvage therapy should generally not be
offeredHDTwithASCTsincethesepatientsdonotbenefit
from this treatment approach.
Conclusions
In summary, our results confirm that HDT and ASCT is a
highly effective therapy leading to long-term survival in a
substantial proportion of non-selected patients with
DLBCL. In our series, high-risk patients receiving HDT
followed by ASCT as part of their 1
st-line therapy, patients
withincompleteresponsetoconventionalfirst-linetherapy
but chemosensitive disease as well as patients with
chemosensitiverelapseachievehighremissionrateswith
the majority having a good long-term prognosis. In con-
trast, patients with primary refractory chemoresistant
disease and patients with relapsed disease lacking
chemosensitivity do not benefit from HDT with ASCT and
shouldbecandidatesforeithertreatmentswithpalliative
intent or experimental approaches.
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